DECN Today Launches its GenUltimate TGB Product into Select International Markets
DECN Awaits Major Counter Proposition from Two Entities as JNJ Litigation Heats up LOS ANGELES, CA June 6, 2019 - Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused FDA Registered bio-technology worldwide company has received a fourth unsolicited proposition for a strategic transaction involving our GenUltimate! TBG system, Read More. See Complete Information: http://www.thestreetnow.com/spotlight/dailynews/.....
Disclaimer: I post on stocks that I own or am thinking about owning, I am not paid to post about them. If that changes you can find the disclosure in my IRP page. Do your DD, buy and sell based on that DD.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.